Designer Bugs: Structural Engineering to Build a Better Mouse Model  by Bhaskaran, Shyam S. & Stebbins, C. Erec
Cell Host & Microbe
PreviewsDesigner Bugs: Structural Engineering
to Build a Better Mouse Model
Shyam S. Bhaskaran1 and C. Erec Stebbins1,*
1 Laboratory of Structural Microbiology, Rockefeller University, New York, NY 10021, USA
*Correspondence: stebbins@rockefeller.edu
DOI 10.1016/j.chom.2007.05.009
Many animal models of bacterial diseases are hampered by differences in tissue tropism and the
course of pathogenesis. In a recent issue of Cell, by rationally mutating a surface invasion protein
(InlA) to have higher binding affinity for its cognate host receptor (E-cadherin), Wollert et al. were
able to ‘‘murinize’’ Listeria monocytogenes, creating a strain capable of invading intestinal epithelial
cells in mice, mimicking the route of infection in humans.Cell Host & Microbe 1, June 2007 ª2007 Elsevier Inc. 241Since the beginnings of germ theory
with Koch, Pasteur, and others in the
mid-19th century, animal models have
been indispensable in the study of hu-
man infectious diseases, in elucidating
not only the basis of their pathogene-
sis but also how our body’s defenses
respond to this invasion. The mouse
model in particular has proven attrac-
tive due to its relatively low-mainte-
nance costs, high fecundity, geneti-
cally pure strains, and a biochemistry
and physiology similar to that of
humans (99% of its 30,000 genes
have a sequence homolog in humans,
96% of which are within syntenic
chromosomal regions). Moreover, the
organism is genetically tractable, with
tools such as targeted mutagenesis
(gene knockouts/ins) and RNAi avail-
able to manipulate gene expression.
Additionally, the presence of both an
innate and adaptive immune system
allows the dissection of evolving inter-
actions between host and pathogen
during disease (Pradel and Ewbank,
2004).
However, some human pathogens
exhibit strong species and tissue-
specific tropism, not infecting mice or
having a disease progression that is
markedly different from that in humans.
For example, Salmonella enterica
serovar Typhi causes potentially fatal
typhoid fever in humans but cannot
establish an infection in mice, whereas
Salmonella enterica serovar Typhimu-
rium causes a limited gastrointestinal
infection in humans but a systemic
fatal infection in mice. When the basis
of species tropism is understood,
commonly the specific interaction ofa pathogen ligand and a cell-surface
receptor, one solution is to construct
a transgenic mouse carrying the hu-
man homolog of the receptor in addi-
tion to that of the mouse, expressed
in either specific tissues or the whole
organism (Figure 1). This was first
done with the polio virus, where mice
carrying the human receptor CD155
(hPVR) and its promoter exhibited
lethal poliomyelitis when infected in-
tracerebrally, while normal mice were
not susceptible (Ren et al., 1990).
The first bacterial pathogen with
a ‘‘humanized’’ mouse model was the
Gram-positive food-borne pathogen
Listeria monocytogenes. Listeriosis
has a mortality rate of30%, affecting
mostly fetuses, newborns, and immu-
nocompromised patients, leading tosevere gastroenteritis, miscarriage,
and meningitis. It is of particular con-
cern because the bacterium continues
to grow at refrigerated temperatures,
and food contamination can lead to
major outbreaks. Furthermore, it is
one of the few bacterial pathogens
that can cross the intestinal barrier,
the blood-brain barrier, as well as the
fetoplacental barrier. It is able to do
so by stimulating its uptake into non-
phagocytic cells (thereby also evading
the immune system) through the use of
two internalins: InlA which interacts
with the adhesion molecule E-cad-
herin present in epithelial cell-cell junc-
tions and leads to entry into intestinal
cells (Mengaud et al., 1996), and InlB
which binds the receptor tyrosine
kinase Met leading to invasion ofFigure 1. Overcoming Species- and Tissue-Specific Tropism
(A) The L. monoctyogenes invasin InlA is unable to bind the murine homolog of its receptor,
E-cadherin.
(B) Human E-cadherin can be expressed ubiquitously or in specific tissues in transgenic mice.
(C) InlA can be modified to bind murine E-cadherin.
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lines (Shen et al., 2000). After escape
from the phagosome, it can rapidly
multiply cytoplasmically and move
from cell to cell using the actin cyto-
skeleton, as well as spreading to the
liver and other organs through the
bloodstream and lymphatic system.
In mice, InlB can bind Met, but InlA is
unable to bind E-cadherin, specifically
due to a change of Pro16 to glutamic
acid, making them resistant to oral in-
fection (Lecuit et al., 1999). Therefore,
only intravenous infections were pos-
sible until a transgenic mouse was
created that specially expressed hu-
man E-cadherin (hE-cadherin) in intesti-
nal epithelial cells under the control of
the intestinal fatty-acid binding-protein
(iFABP) promoter (Lecuit et al., 2001).
This then allowed researchers to study
the early stages of oral listeriosis. How-
ever, there is a major limitation inherent
in the model. Since the expression of
hE-cadherin was restricted specifically
to the intestines, the mechanism by
which L. monocytogenes crossed the
blood-brain and fetoplacental barrier
could not be addressed in the model,
despite being of great clinical interest.
One possible solution was to chromo-
somally replace the mouse coding se-
quence with its human homolog, but
this risked thecomplication that interac-
tions with other partners of E-cadherin
could be affected. Another approach
would be to devise a mouse model
that retained the endogenous expres-
sion pattern of host receptors but which
interacted with both InlA and InlB.
In their recent study in Cell, Wollert
and colleagues were able to do just
this. Through a structure-based engi-
neering approach, they were able to
create a strain of L. monocytogenes
containing a modified InlA that could
bind murine E-cadherin. This strain
was able to lethally infect mice by the
intragastric route, recapitulating the
symptoms of both oral and systemic
listeriosis (Wollert et al., 2007).
This reengineering was based on
a previously determined crystal struc-
ture of a complex between InlA and
the N-terminal cytoplasmic domain of
hE-cadherin (hEC1) (Schubert et al.,
2002; Figure 2). It was hypothesized
that the binding affinity of InlA to its re-
ceptor could be enhanced by making242 Cell Host & Microbe 1, June 2007 ª2Figure 2. Structural Basis for the Murinizing of Listeria
(A) Structural alignment of the complexes InlAWT/hEC1 (magenta, PDB 1O6S) and InlAm/mEC1
(green, coordinates obtained from W. Schubert). The positions of the two point mutations in InlAm
are also shown (red).
(B) Illustration of the new hydrogen bond between Asn192 (InlAm) and the carbonyl of Phe17
(mEC1). Also shown are Pro16 (hEC1) and Glu16 (mEC1).
(C) Illustration of the new water-mediated hydrogen bond from Ser369 (InlAm) to Asn27 (mEC1).two amino acid changes in InlA that
would improve its surface comple-
mentarity to hEC1. Ser192InlA was mu-
tated to a slightly longer asparagine
residue, allowing it to form a hydrogen
bond to the main-chain carbonyl of
Phe17hEC1, and a bulky Tyr369InlA
which had unfavorable steric interac-
tions with Asn27hEC1 was replaced by
a smaller serine residue. Their crystal
structure of the (double) mutant pro-
tein (InlAm) with hEC1 confirmed that
Asn192InlAm did actually form a hydro-
gen bond to the carbonyl of Phe17hEC1
and also that Ser369InlAm formed a
new water-mediated hydrogen bond
to Asn27hEC1. As a result, the binding
affinity (KD) of InlA
m to hEC1 had in-
creased 6700-fold to 1.2 ± 0.3 nM
from 8 ± 4 mM for InlA. Additionally,
the invasion efficiency of an isogenic
mutant strain (Lmo-InlAm) into human
epithelial cell lines was doubled com-
pared to the wild-type strain (Lmo-WT),
but not changed in a macrophage-
like cell line where uptake is phago-
cytotic and internalin independent.
Surprisingly, InlAm was now also
able to bind murine EC1 (mEC1), with
a KD of 10 ± 2 mM, comparable to007 Elsevier Inc.that of wild-type InlA to hEC1. More-
over, the modified Lmo-InlAm strain
was 1000-fold more virulent than
Lmo-WT when administered orally to
mice. At the highest doses used, the
mutant strain was 100% lethal within
5 days, while the wild-type caused
only 20% mortality by 2 weeks. Bac-
terial loads in the stomach, small intes-
tine, mesenteric lymph nodes, spleen,
and liver were also significantly higher
and increased steadily during infection
with Lmo-InlAm, but stabilized 2 days
postinfection with Lmo-WT. Immuno-
histochemical analyses showed that
Lmo-WT did not invade epithelial cells,
most likely crossing the intestinal
barrier through phagocytic M cells
present in Peyer’s patches. In contrast,
Lmo-InlAm quickly colonized the epi-
thelia at the tips of the villi and rapidly
spread through the rest of the epithe-
lial and subepithelial layers. This is
consistent with the idea that the baso-
laterally expressed E-cadherin is only
exposed at the tips of microvilli as cells
are sloughing off (Lecuit et al., 2001).
Interestingly, when administered intra-
venously, both strains were identical in
virulence and organ loads, showing
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spread.
Previous work in human placental
explants and trophoblastic cells (Le-
cuit et al., 2004) had shown a role for
InlA in crossing the fetoplacental bar-
rier, while studies in mice (nonfunc-
tional InlA; Le Monnier et al., 2007)
and guinea pigs (nonfunctional InlB;
Bakardjiev et al., 2004) showed no re-
quirement for either. In this study, the
authors found no difference in placen-
tal loads between strains when infect-
ing pregnant mice, indicating that
another mechanism must be present
for crossing this barrier. This result
could only have been conclusively de-
termined using this model (functional
InlA and InlB) and hopefully will yield
further insights into the poorly under-
stood mechanisms behind how both
the fetoplacental and the blood-brain
barrier are crossed.
The possibility that the concept of
‘‘murinizing’’ the pathogen rather than
‘‘humanizing’’ the host could be ex-
panded to other pathogens where suit-
able animal models have not been cre-
ated is tremendously exciting. This
would provide an alternative to the cre-
ation of transgenic mice, where certain
pitfalls, such as secondary effects of
additionally expressed receptors and
strain background effects on the host
response, can complicate the effec-tiveness of the model. Bacterial genet-
ics also requires significantly less effort
than creating a stable transgenic line.
However, since one cannot change
what one does not understand, and in
many cases the exact reason for spe-
cies-tropism is unknown, the general
applicability of this approach may be
limited. Nevertheless, when such infor-
mation is present, it is likely to prove
a valuable tool of great utility in under-
standing bacterial pathogenesis.
Finally, while exciting for the devel-
opment of new infection models, it
is also concerning that in this case
a pathogen’s host range could be
expanded by only two amino acid
changes, especially in the context of
emerging infectious diseases, where
changes in host susceptibility has the
potential to lead to global pandemics,
as has happened with HIV and could
occur with avian flu. And as with
many insights into the ability to manip-
ulate an infectious agent, concerns
arise regarding how such paradigms
might be applied for nefarious pur-
poses. However, as a corollary, these
same molecular determinants of viru-
lence may prove to be the pathogen’s
Achilles’ heel and raise the promise
of rationally designed small-molecule
drugs that disrupt these few inter-
actions between host receptor and
microbial ligand.Cell Host & MicroREFERENCES
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